Derivative

PIMCO Energy and Tactical Credit Opportunities Fund Declares Quarterly Common Share Distributions

Monday, March 1, 2021 - 9:34pm

A return of capital is not taxable; rather it reduces a shareholders tax basis in his or her shares of the Fund.

Key Points: 
  • A return of capital is not taxable; rather it reduces a shareholders tax basis in his or her shares of the Fund.
  • Any recharacterization of payments made or received by the Fund pursuant to derivatives potentially could affect the amount, timing or character of Fund distributions.
  • If you sell your common shares of the Fund, the price received may be more or less than your original investment.
  • PIMCO undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statement.

BOINGO ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of WIFI and Encourages Investors to Contact the Firm

Monday, March 1, 2021 - 4:20pm

On March 1, 2021, Boingo announced that it had signed an agreement to be acquired by Digital Colony for approximately $854 million.

Key Points: 
  • On March 1, 2021, Boingo announced that it had signed an agreement to be acquired by Digital Colony for approximately $854 million.
  • Pursuant to the merger agreement, Boingo stockholders will receive $14 in cash for each share of Boingo common stock owned.
  • Bragar Eagel & Squire is concerned that Boingos board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Monday, March 1, 2021 - 3:05pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Monday, March 1, 2021 - 3:05pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - Tibra Trading PTY Limited: APPLEGREEN PLC

Monday, March 1, 2021 - 3:05pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Friday, February 26, 2021 - 3:06pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Friday, February 26, 2021 - 3:05pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Global Soy Bean Derivatives Market Report 2021 - Size, Share, COVID Impact Analysis and Forecast 2020-2027 - ResearchAndMarkets.com

Friday, February 26, 2021 - 2:55pm

The "2021 Soy Bean Derivatives Market - Size, Share, COVID Impact Analysis and Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2021 Soy Bean Derivatives Market - Size, Share, COVID Impact Analysis and Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • 2021 Soy Bean Derivatives Market - Size, Share, COVID Impact Analysis and Forecast to 2027 - is comprehensive research with in-depth data and contemporary analysis of Soy Bean Derivatives Market at a global, regional and key country level, split by different sub-segments of the industry.
  • Fast pace recovery of developing economies leading to increased disposable income will support the Soy Bean Derivatives Market demand between 2021 and 2027.
  • Lockdowns across the globe in 2020 and continuing restrictions in 2021 disrupted the supply chain posing challenges for manufactures in the Soy Bean Derivatives Market.

$1.2 Billion Worldwide Animal Blood Plasma Products and Derivatives Industry to 2027 - Impact of COVID-19 on the Market

Thursday, February 25, 2021 - 8:15pm

DUBLIN, Feb. 25, 2021 /PRNewswire/ -- The "Animal Blood Plasma Products and Derivatives - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 25, 2021 /PRNewswire/ -- The "Animal Blood Plasma Products and Derivatives - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 143-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • Amid the COVID-19 crisis, the global market for Animal Blood Plasma Products and Derivatives estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$1.8 Billion by 2027, growing at a CAGR of 6.5% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $343.7 Million, While China is Forecast to Grow at 6.1% CAGR
    The Animal Blood Plasma Products and Derivatives market in the U.S. is estimated at US$343.7 Million in the year 2020.

PANDION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PAND and Encourages Investors to Contact the Firm

Thursday, February 25, 2021 - 4:49pm

On February 25, 2021, Pandion announced that it had signed an agreement to be acquired by Merck for approximately $1.85 billion.

Key Points: 
  • On February 25, 2021, Pandion announced that it had signed an agreement to be acquired by Merck for approximately $1.85 billion.
  • Pursuant to the merger agreement, Pandion stockholders will receive $60 in cash for each share of Pandion common stock owned.
  • Bragar Eagel & Squire is concerned that Pandions board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.